DeepMed Research

Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

Clinical Study on the Safety of Double and a Half Layered Esophagojejunal Anastomosis in Curative Gastrectomy

Not Applicable

Conditions: Surgery--Complications

Interventions: Procedure: double and a half layered esophagojejunal anastomosis

First Posted Date: 2022-03-16

Last Posted Date: 2022-03-16

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 21

Registration Number: NCT05282563

Locations: 🇨🇳
Henan cancer hopital, Zhengzhou, Henan, China

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Not Applicable

Recruiting

Conditions: Intraoperative Complications
Perfusion; Complications
High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions: Device: hyperthermic intravesical perfusion

First Posted Date: 2022-03-11

Last Posted Date: 2022-09-16

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05276167

Locations: 🇨🇳
BR-PRG, Zhengzhou, Henan, China

An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: herombopag olamine tablets

First Posted Date: 2022-02-23

Last Posted Date: 2022-02-23

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05252091

Anti-emetic Prophylaxis With or Without Dexamethasone

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen
Drug: Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen

First Posted Date: 2022-02-16

Last Posted Date: 2024-10-10

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 442

Registration Number: NCT05242874

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
🇨🇳
Henan cacer hospital, Henan, Henan, China

PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.

Phase 2

Not yet recruiting

Conditions: Cholangiocarcinoma

Interventions: Drug: Sintilimab

First Posted Date: 2022-01-26

Last Posted Date: 2022-01-26

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 73

Registration Number: NCT05207735

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Phase 2

Recruiting

Conditions: Central Nervous System Lymphoma

Interventions: Drug: ICP-022
Drug: Pemetrexed

First Posted Date: 2022-01-26

Last Posted Date: 2025-04-23

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05209620

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Albumin-Bound Paclitaxel
Drug: Camrelizumab

First Posted Date: 2022-01-12

Last Posted Date: 2024-02-07

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05189483

Locations: 🇨🇳
Department of Bone and Soft Tissue, Henan Cancer Hospital, Zhengzhou, Henan, China

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Phase 1

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Famitinib
Drug: SHR6390
Drug: Fulvestrant

First Posted Date: 2022-01-04

Last Posted Date: 2024-12-17

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 46

Registration Number: NCT05176080

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: fruquintinib + sintilimab + SOX

First Posted Date: 2022-01-04

Last Posted Date: 2022-08-19

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 42

Registration Number: NCT05177068

Locations: 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

Not Applicable

Not yet recruiting

Conditions: Recurrent Hepatocellular Cancer

Interventions: Drug: toripalimab
Drug: Lenvatinib
Device: Radiofrequency ablation

First Posted Date: 2021-12-17

Last Posted Date: 2022-01-27

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 90

Registration Number: NCT05162898

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy